Loading clinical trials...
Loading clinical trials...
A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza Infection
Conditions
Interventions
DAS181
Placebo
Locations
1
China
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, China
Start Date
July 1, 2020
Primary Completion Date
March 1, 2021
Completion Date
September 1, 2022
Last Updated
July 9, 2020
NCT06998251
NCT04933968
NCT03392389
NCT01049490
NCT00812448
NCT00239213
Lead Sponsor
Ansun Biopharma, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions